Clearside Biomedical (NASDAQ:CLSD) Stock Rating Upgraded by Wall Street Zen

Clearside Biomedical (NASDAQ:CLSD) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

CLSD has been the subject of several other reports. HC Wainwright cut shares of Clearside Biomedical from a “buy” rating to a “neutral” rating and set a $75.00 target price for the company. in a research note on Friday, July 18th. Stifel Nicolaus cut shares of Clearside Biomedical from a “buy” rating to a “hold” rating and set a $30.00 target price for the company. in a research note on Friday, July 18th. Chardan Capital cut shares of Clearside Biomedical from a “buy” rating to a “neutral” rating in a research note on Friday, July 18th. Needham & Company LLC cut shares of Clearside Biomedical from a “moderate buy” rating to a “hold” rating and set a $45.00 target price for the company. in a research note on Thursday, July 17th. Finally, Jones Trading cut shares of Clearside Biomedical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. One analyst has rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, Clearside Biomedical has a consensus rating of “Hold” and an average target price of $63.00.

Clearside Biomedical Stock Up 2.6%

Shares of CLSD opened at $3.90 on Friday. The stock has a market capitalization of $20.44 million, a P/E ratio of -0.70 and a beta of 2.05. Clearside Biomedical has a twelve month low of $3.32 and a twelve month high of $17.40. The company has a 50 day moving average of $4.62 and a 200-day moving average of $8.78.

Clearside Biomedical (NASDAQ:CLSD) last issued its quarterly earnings results on Friday, August 8th. The company reported ($0.90) earnings per share for the quarter, topping the consensus estimate of ($1.80) by $0.90. The business had revenue of $0.49 million for the quarter, compared to the consensus estimate of $0.50 million. On average, sell-side analysts anticipate that Clearside Biomedical will post -0.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Clearside Biomedical

A hedge fund recently bought a new stake in Clearside Biomedical stock. Apollon Wealth Management LLC purchased a new stake in shares of Clearside Biomedical, Inc. (NASDAQ:CLSD) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 23,586 shares of the company’s stock, valued at approximately $94,000. Apollon Wealth Management LLC owned about 0.45% of Clearside Biomedical at the end of the most recent reporting period. Institutional investors and hedge funds own 18.75% of the company’s stock.

About Clearside Biomedical

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.